Skip to content
10-Q

Quarterly Report

AbCellera Biologics Inc. ABCL

0001703057-26-000028

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 305.38M sh
Shares Diluted Q1 2026 · Mar 31, 2026 303.07M sh
Shares Diluted Q1 2026 · Mar 31, 2025 297.69M sh
Capex Q1 2026 · Mar 31, 2026 $3.83M
Capex Q1 2026 · Mar 31, 2025 $10.64M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$33.52M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$11.55M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $77.06M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $128.51M
Stockholders Equity Q1 2026 · Mar 31, 2026 $938.08M
Stockholders Equity Q1 2026 · Dec 31, 2025 $966.9M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.02B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.06B
Current Liabilities Q1 2026 · Mar 31, 2026 $47.29M
Current Liabilities Q1 2026 · Dec 31, 2025 $64.31M
Total Liabilities Q1 2026 · Mar 31, 2026 $369.03M
Total Liabilities Q1 2026 · Dec 31, 2025 $390.05M
Current Assets Q1 2026 · Mar 31, 2026 $664.6M
Current Assets Q1 2026 · Dec 31, 2025 $728.23M
Total Assets Q1 2026 · Mar 31, 2026 $1.31B
Total Assets Q1 2026 · Dec 31, 2025 $1.36B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.14
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.14
Eps Basic Q1 2026 · Mar 31, 2025 −$0.15
Sga Expense Q1 2026 · Mar 31, 2026 $12.33M
Sga Expense Q1 2026 · Mar 31, 2025 $19.07M
Rd Expense Q1 2026 · Mar 31, 2026 $46.66M
Rd Expense Q1 2026 · Mar 31, 2025 $42.5M
Net Income Q1 2026 · Mar 31, 2026 −$43.17M
Net Income Q1 2026 · Mar 31, 2025 −$45.62M
Operating Income Q1 2026 · Mar 31, 2026 −$57.52M
Operating Income Q1 2026 · Mar 31, 2025 −$62.66M
Revenue Q1 2026 · Mar 31, 2026 $8.32M
Revenue Q1 2026 · Mar 31, 2025 $4.24M